AFFILIATIONS
1 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
2 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
3 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
4 The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
5 Fudan University Cancer Hospita, Shanghai, China
6 Fudan University Cancer Hospita, Shanghai, China
7 The First Hospital of Lanzhou University, Lanzhou, China
8 The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
9 The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
10 Beijing Tongren Hospital, Beijing, China
11 The First People's Hospital of Foshan, Foshan, China
12 Ganzhou Cancer Hospital, Ganzhou, China
13 Gansu Provincial Cancer Hospital, Lanzhou, China
14 Huizhou First People’s Hospital, Huizhou, Guangdong, China
15 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
16 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
17 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
18 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
19 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
20 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Sun Yat-sen University Cancer Center, , P.R. China., Guangzhou, China
21 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicines, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
ABSTRACT
Background: TP53 mutations occur in approximately 20% of diffuse large B-cell lymphoma (DLBCL) cases and are associated with inferior responses and poor outcomes following standard immunochemotherapy. Selinexor, an oral inhibitor of exportin 1 (XPO1), restores nuclear localization of tumor suppressor proteins, including p53, and induces apoptosis via both p53-dependent and p53-independent pathways. This phase II trial (NCT06517511) evaluated the efficacy and safety of selinexor combined with R-CHOP as first-line therapy for patients with TP53-mutated DLBCL.
Methods: Patients with newly diagnosed, untreated DLBCL confirmed to harbor TP53 mutations via next-generation sequencing (NGS)genetic sequencing were enrolled in this study. The induction treatment consisted of six 21-day cycles of selinexor in combination with R-CHOP, followed by two additional cycles of selinexor plus rituximab. To reduce the risk of tumor lysis syndrome, selinexor was introduced from the second cycle at an initial dose of 60 mg, administered on days 1 and 8 of each cycle. Patients who achieved a complete response (CR) after induction treatment continued selinexor as maintenance treatment until disease progression (PD), or intolerable toxicity, or a maximum total treatment duration of two years, whichever occurred first. The primary endpoint was the end-of-treatment (EOT) complete response rate, assessed according to the Lugano 2014 criteria.
Results: Between August 2024 and April 2026, a total of 39 patients were enrolled. Among these participants, 22 had evaluable end-of-treatment response outcomes. The median age was 58 years (IQR, 46–63). Seventeen patients (77.3%) presented with advanced-stage disease (stage III–IV), and 16 (72.7%) had an IPI score ≥2. MYC/BCL2 double expression was identified in 11 patients. The median number of induction treatment cycles was 6 (range, 3–8). The best complete response (CR) rate was 68.2% (15/22), with an overall response rate (ORR) of 90.9% (20/22), and the EOT CR rate was 63.6% (14/22). With a median follow-up of 9.2 months (95% CI, 7.1–15.5), the estimated 1-year progression-free survival (PFS) rate was 68.0%, and no deaths were observed. During induction, the most common adverse events of any grade were leukopenia (86.4%), neutropenia (77.3%), decreased appetite (54.5%), nausea (54.5%), peripheral neuropathy (50.0%), anemia (45.5%), vomiting (45.5%), and thrombocytopenia (40.9%). Grade ≥3 adverse events were primarily leukopenia (50.0%), neutropenia (50.0%), thrombocytopenia (9.1%), and anemia (4.5%). Infections occurred in 3 patients (13.6%). Overall, the safety profile was manageable with supportive care and dose modifications.
Conclusion: In this phase II trial, selinexor plus R-CHOP showed encouraging efficacy with a manageable safety profile in patients with TP53-mutated DLBCL. These findings highlight the potential of selinexor-based combinations as a treatment strategy for this high-risk population.